Applied Therapeutics, Inc. Overview
Pro stress-test →Applied Therapeutics was acquired by Cycle Group Holdings on February 3, 2026, concluding its journey as a clinical-stage biopharmaceutical company. The company developed govorestat (AT-007), a CNS-penetrant Aldose Reductase Inhibitor for rare metabolic diseases including Classic Galactosemia, CMT-SORD Deficiency, and PMM2-CDG.
Strategic Profile
Pro stress-test →Before acquisition, Applied Therapeutics reduced workforce by approximately 46% and implemented cost-containment measures, reflecting challenges in its development pipeline. The company completed FDA Type C meetings for govorestat in CMT-SORD and received FDA written feedback on galactosemia data, evaluating next steps.
Competitive Landscape
Pro stress-test →Govorestat competes in the rare metabolic disease treatment space, targeting CNS-penetrant aldose reductase inhibition for galactosemia and sorbitol dehydrogenase deficiency. The acquisition by Cycle Group reflects consolidation in the biotech sector where smaller clinical-stage companies face significant capital and regulatory hurdles.
Industry Context
Applied Therapeutics, Inc. operates in Clinical-stage Biopharmaceuticals / Rare Metabolic Diseases.
Key facts
Founded: 2016 · Headquarters: New York, United States